Damora Therapeutics, Inc. (DMRA): Submission of Matters to a Vote of Security Holders
Damora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001800315 0001800315 2026-04-28 2026-04-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17 ,
How this was made
The 30-second read
Why it matters
The disclosure confirms director re-elections and advisory compensation vote results, plus auditor ratification for FY ending Dec. 31, 2026; it does not introduce new business, financial, or regulatory developments.
Market read
Primarily governance/administrative confirmation; not a catalyst for earnings or risk repricing.
What to watch
Traders may watch for follow-on disclosures (e.g., subsequent 10-Q/8-K items) rather than the meeting vote tallies themselves.
Background
The company submitted Form 8-K Item 5.07 summarizing matters voted on at its June 17, 2026 annual meeting, referencing its April 29, 2026 proxy statement.
Ticker impact
Damora Therapeutics filed an 8-K detailing 2026 annual meeting results, including election of directors and advisory say-on-pay/frequency votes.
Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.
The filing reports voting tallies and board re-election, with no new financial guidance, clinical/regulatory updates, or material corporate actions.
Market effects
Minimal; governance vote outcomes generally do not reset sector risk or read-across.
Minimal; Nasdaq-listed microcap filing with no broader market catalyst.
Minimal; no international transaction or regulatory action disclosed.
Counterpoint
If the market had been pricing uncertainty around board composition or executive compensation, the clear vote outcomes could reduce overhang, but the filing still lacks new operating catalysts.
Key entities
- companyDamora Therapeutics, Inc.
Nasdaq-listed issuer filing the 8-K with annual meeting voting results (Item 5.07).
- director_nomineeMichael Landsittel
Elected as Class III board member at the annual meeting.
- director_nomineeCameron Turtle, D.Phil
Elected as Class III board member at the annual meeting.
- auditorErnst & Young LLP
Ratified as independent registered public accounting firm for FY ending Dec. 31, 2026.
